Compare Stocks

Date Range: 

 Eagle PharmaceuticalsSIGA TechnologiesRelmada TherapeuticsCrinetics PharmaceuticalsMirum Pharmaceuticals
SymbolNASDAQ:EGRXNASDAQ:SIGANASDAQ:RLMDNASDAQ:CRNXNASDAQ:MIRM
Price Information
Current Price$41.65$7.33$36.34$16.96$18.67
52 Week RangeN/AN/ABuyBuyBuy
MarketRank™
Overall Score1.00.31.11.81.8
Analysis Score0.00.03.33.43.6
Community Score2.90.01.42.22.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.83.32.5
Earnings & Valuation Score0.61.30.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/ABuyBuyBuy
Consensus Price TargetN/AN/A$57.50$36.75$40.17
% Upside from Price TargetN/AN/A58.23% upside116.69% upside115.14% upside
Trade Information
Market Cap$546.41 million$557.56 million$608.59 million$637.58 million$568.35 million
Beta0.740.530.531.242.44
Average Volume117,341265,01369,727136,517127,498
Sales & Book Value
Annual Revenue$195.89 million$26.74 millionN/A$1.19 millionN/A
Price / Sales2.7920.85N/A535.78N/A
Cashflow$1.52 per shareN/AN/AN/AN/A
Price / Cash27.49N/AN/AN/AN/A
Book Value$13.11 per share$1.21 per share$7.88 per share$4.84 per share$5.67 per share
Price / Book3.186.06N/A3.50N/A
Profitability
Net Income$14.31 million$-7,240,000.00N/A$-50,420,000.00$-52,550,000.00
EPS$1.38N/A($2.16)($2.09)($4.58)
Trailing P/E Ratio119.0018.33N/AN/AN/A
Forward P/E Ratio138.83N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins2.65%34.62%N/AN/AN/A
Return on Equity (ROE)8.50%37.31%-32.03%-43.35%-61.90%
Return on Assets (ROA)5.44%25.33%-31.41%-39.73%-54.46%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.16%N/AN/AN/AN/A
Current Ratio3.60%8.04%37.02%21.98%7.35%
Quick Ratio3.45%7.38%37.02%21.98%7.35%
Ownership Information
Institutional Ownership Percentage95.12%29.28%64.31%92.15%72.90%
Insider Ownership Percentage21.10%3.91%9.30%7.10%45.50%
Miscellaneous
Employees10642149368
Shares Outstanding13.12 million76.07 million16.75 million37.59 million30.44 million
Next Earnings Date5/10/2021 (Confirmed)8/5/2021 (Estimated)N/A8/6/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateMirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
businesswire.com - May 7 at 2:16 AM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue EstimatesMirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates
nasdaq.com - May 6 at 9:15 PM
Mirum Pharmaceuticals Inc to Host Earnings CallMirum Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - May 6 at 4:15 PM
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by BrokeragesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - May 2 at 2:20 AM
Mirum Pharmaceuticals Inc (MIRM)Mirum Pharmaceuticals Inc (MIRM)
investing.com - April 30 at 2:22 PM
Mirum Pharmaceuticals (MIRM) Set to Announce Quarterly Earnings on ThursdayMirum Pharmaceuticals (MIRM) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - April 30 at 9:58 AM
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
finance.yahoo.com - April 29 at 7:47 PM
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater ChinaMirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China
us.acrofan.com - April 29 at 9:40 AM
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver DiseasesMirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
finance.yahoo.com - April 29 at 9:40 AM
Mirum Pharmaceuticals (NASDAQ:MIRM) Is In A Good Position To Deliver On Growth PlansMirum Pharmaceuticals (NASDAQ:MIRM) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - April 27 at 9:24 AM
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille SyndromeMirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
finance.yahoo.com - April 26 at 1:01 PM
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down to $18.63Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down to $18.63
americanbankingnews.com - April 22 at 12:52 PM
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $17.86Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $17.86
americanbankingnews.com - April 21 at 12:56 PM
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $18.00Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $18.00
americanbankingnews.com - April 14 at 12:42 PM
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial ...Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial ...
businesswire.com - April 12 at 11:30 PM
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic CholestasisMirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
finance.yahoo.com - April 12 at 1:29 PM
Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille SyndromeMirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
finance.yahoo.com - March 29 at 12:50 PM
Mirum Pharmaceuticals IncMirum Pharmaceuticals Inc
reuters.com - March 17 at 3:23 PM
Have Insiders Been Buying Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares?Have Insiders Been Buying Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares?
finance.yahoo.com - March 13 at 6:13 PM
Mirum Pharmaceuticals (MIRM) Receives a Buy from Leerink PartnersMirum Pharmaceuticals (MIRM) Receives a Buy from Leerink Partners
smarteranalyst.com - March 11 at 1:12 PM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business UpdatesMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
finance.yahoo.com - March 9 at 8:47 PM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue EstimatesMirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 9 at 8:47 PM
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)
finance.yahoo.com - March 9 at 10:46 AM
Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille SyndromeMirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome
finance.yahoo.com - February 1 at 1:06 PM
Mirum Pharmaceuticals Honors Alagille SyndromeAwareness Day with Launch of Disease Awareness CampaignMirum Pharmaceuticals Honors Alagille SyndromeAwareness Day with Launch of Disease Awareness Campaign
marketwatch.com - January 24 at 5:38 PM
DateCompanyBrokerageAction
4/20/2020Eagle PharmaceuticalsCantor FitzgeraldReiterated Rating
3/25/2020Eagle PharmaceuticalsRoyal Bank of CanadaReiterated Rating
4/24/2019Eagle PharmaceuticalsMizuhoReiterated Rating
10/31/2018Eagle PharmaceuticalsPiper Jaffray CompaniesDowngrade
3/17/2021Relmada TherapeuticsOppenheimerReiterated Rating
10/28/2020Relmada TherapeuticsThe Goldman Sachs GroupDowngrade
5/4/2020Relmada TherapeuticsSunTrust BanksInitiated Coverage
1/27/2020Relmada TherapeuticsJefferies Financial GroupInitiated Coverage
1/10/2020Relmada TherapeuticsSVB LeerinkReiterated Rating
12/16/2019Relmada TherapeuticsGuggenheimInitiated Coverage
5/3/2021Crinetics PharmaceuticalsJonestradingInitiated Coverage
11/9/2020Crinetics PharmaceuticalsHC WainwrightReiterated Rating
10/14/2020Crinetics PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
12/23/2019Crinetics PharmaceuticalsRoth CapitalInitiated Coverage
4/1/2021Mirum PharmaceuticalsRobert W. BairdReiterated Rating
11/13/2020Mirum PharmaceuticalsRaymond JamesBoost Price Target
9/1/2020Mirum PharmaceuticalsCitigroupBoost Price Target
7/30/2020Mirum PharmaceuticalsPiper SandlerInitiated Coverage
8/12/2019Mirum PharmaceuticalsEvercore ISIInitiated Coverage
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.